Abstract: Described are modified T cells overexpressing one or more glucose transporters. Pharmaceutical compositions containing the glucose transporter overexpressing T cells are also described. The glucose transporter overexpressing T cells and pharmaceutical compositions can be used in adoptive cell therapies.

Abstract: The novel synergistic combination of immune checkpoint blockade and hematopoietic stem cell transplantation and/or hematopoietic stem cell mobilization yield synergistic effects in disease therapy.

Abstract: Provided herein is a method of improving sensitivity of a tumor to a host immune response, the method comprising administering to a subject in need thereof a Type I interferon and an immune checkpoint inhibitor, thereby increasing sensitivity of the tumor to a host immune response.

Abstract: Cell-based compositions and methods for targeting and treating human diseases, including cancers and infectious diseases, are provided, wherein exogenous intracellular sarcosine is used for improved delivery of the composition.

Abstract: The present disclosure provides a nanoparticle comprising a positively-charged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, wherein each nucleic acid layer is positioned between a cationic lipid bilayer, wherein the nanoparticle comprises RNA molecules encoding a SARS-CoV-2 protein. Methods of making such nanoparticles are further provided herein. Additionally, related cells, populations of cells, pharmaceutical compositions comprising the presently disclosed nanoparticles are provided. Methods of increasing an immune response against a tumor in a subject, methods of delivering RNA molecules to an intra-tumoral microenvironment, lymph node, and/or a reticuloendothelial organ in a subject, and methods of treating a subject with a disease are furthermore provided.

Abstract: Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4+ T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy.

Abstract: The disclosure provides methods of treating coronavirus infections (e.g., COVID-19) by administering hematopoietic stem cells, with or without an immune checkpoint inhibitor (e.g., PD-1 antagonist). The disclosure also provides methods of treating coronavirus infections (e.g., COVID-19) by adoptive cell transfer of polyclonal T cells and coronavirus-specific T cells (e.g., SARS-CoV-2-specific T cells).

Abstract: Cell-based compositions and methods for targeting and treating human diseases, including cancers and infectious diseases, are provided, wherein exogenous intracellular sarcosine is used for improved delivery of the composition.

Abstract: Provided herein are compositions comprising a liposome comprising ribonucleic acid (RNA) molecules and a cationic lipid, wherein the RNA molecules bind to or encode an epitope of a nucleic acid encoding a fusion protein expressed by a tumor. The disclosure also provides a nanoparticle comprising a positively-charged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, wherein each nucleic acid layer is positioned between a cationic lipid bilayer, and nucleic acid molecules in the nucleic acid layers comprise a sequence of a nucleic acid molecule expressed by slow-cycling cells (SCCs). Also provided herein re methods of making a nanoparticle and methods of increasing an immune response against a tumor in a subject. Methods of treating a subject with a disease are provided herein.

Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.

Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.

Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.

Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.

Abstract: The combination of adoptive cell therapy with CCR2 positive (CCR2+) hematopoietic stem cell transplantation increases T cell activation and survival.

Abstract: The present disclosure provides a nanoparticle comprising a positively-charged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, wherein each nucleic acid layer is positioned between a cationic lipid bilayer. Methods of making such nanoparticles are further provided herein. Additionally, related cells, populations of cells, pharmaceutical compositions comprising the presently disclosed nanoparticles are provided. Methods of increasing an immune response against a tumor in a subject, methods of delivering RNA molecules to an intra-tumoral microenvironment, lymph node, and/or a reticuloendothelial organ in a subject, and methods of treating a subject with a disease are furthermore provided.

Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.

Abstract: Provided herein are compositions comprising a liposome comprising RNA molecules and a cationic lipid, wherein the RNA molecules encode at least one MHC Class II epitope of a mutant Histone 3 (H3) protein comprising a K27M mutation and optionally at least one MHC Class I epitope of the mutant H3 protein. In exemplary embodiments, the RNA molecules comprise a sequence of SEQ ID NO: 12 or 14. Methods of increasing central memory T cells, increasing an immune response, or treating a diffuse midline glioma (DMG), in a subject are provided herein. In exemplary embodiments, the methods comprise administering to the subject the compositions provided herein.

Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.

Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.

Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.